The content of the narrative reviews in this Series was designed to provide non-dermatologist readers with a better perspective on the value of clinical observation and translational research focused on the cutaneous manifestations of genetically-complex, environmentally-impacted and variably-expressed human illnesses such as the autoimmune connective tissue diseases.
Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders
The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?
AB001. Understanding transcriptional connections of chronic cutaneous lupus erythematosus between humans and animal models
AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials
AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus
AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus
AB007. Worse skin disease severity may distinguish patients who progress from cutaneous lupus erythematous to systemic lupus erythematous
AB008. Utility of repeat latent tuberculosis testing in patients with immune-mediated diseases taking biologics
AB009. Successful treatment of severe systemic lupus erythematosus and psoriasis with IL-17A inhibition
AB011. A Gottron’s papule mimicker: an unusual presentation of porokeratosis plantaris palmaris et disseminata
AB012. Clinical and demographic features of morphea patients with mucocutaneous involvement: a cross sectional study from the morphea of adults and children (MAC cohort)
AB013. CXCL4-DNA immune complexes drive inflammation in systemic sclerosis by amplifying TLR9-mediated interferon-α production
AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study
AB015. Skin disease activity and autoantibody phenotype are major determinants of blood interferon signatures in dermatomyositis
AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis
AB017. Increased dendritic cells and IFN-beta and MxA protein expression in spongiotic dermatitis differentiates dermatomyositis from eczema
AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders
AB019. Response to tofacitinib in a case of refractory TIF-1 positive amyopathic dermatomyositis with arthritis
AB020. A case report on cutaneous necrotizing vasculitis treated with colchicine in a Filipino adult male
AB021. Comparing the performance of two interferon-gamma release assays in autoimmune skin disease patients: a prospective study
AB023. An atypical clinical presentation of alopecia in two patients with systemic lupus erythematosus
The series “Rheumatologic Skin Disease” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Richard D. Sontheimer, M. Kari Connolly, David Fiorentino and Dr. Victoria Werth served as the unpaid Guest Editors for the series.